Recommendations for healthcare professionals on the diagnosis and treatment of myasthenic syndromes, including patient informed consent forms

New treatment options for myasthenic syndromes have constantly been developed over the past few years. In addition to the tried and tested preparations, new medications are increasingly being used. This is a development that offers great opportunities on the one hand, but also brings potential risks and uncertainties for practitioners on the other.

Treatment decisions become major challenges. To support neurologists in this field, the German Myasthenia Society e.V. (DMG) provides this quality manual. This was drawn up by experienced doctors from the DMG Medical Advisory Board in close cooperation with the KKNMS and is updated at regular intervals.